However, there have also been reports of PML associated with drugs utilized in RA management, such as MTX, rituximab (RIT), oral glucocorticoid (GC), and tumor necrosis factor-α inhibitor (TNFi) (Berger et al., 2018). The gene discussed is TNF; the disease is progressive multifocal leukoencephalopathy.